Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

405
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
405
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

605
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
605
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence01:19

Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

242
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
242
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

648
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
648
Therapeutic Index01:13

Therapeutic Index

7.4K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
7.4K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

2.0K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative Effects of Individual Glucagon-Like Peptide-1 Receptor Agonist-Based Medications on Direct Measurement of Body Composition Among Adults With Overweight or Obesity With or Without Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials.

Diabetes, obesity & metabolism·2026
Same author

Analysing complex interventions using component network meta-analysis.

BMJ (Clinical research ed.)·2026
Same author

Updating the PRISMA reporting guideline for scoping reviews: a scoping review.

Journal of clinical epidemiology·2026
Same author

Patient and public involvement in health technology assessments: study protocol for a cross-sectional analysis.

Gaceta sanitaria·2026
Same author

Assessing the impact, uptake and use of reporting guidelines for patient and public involvement in research: GRIPP2 - study protocol for a meta-research project.

BMJ open·2026
Same author

Indirect Comparison of Nipocalimab Versus Efgartigimod and Rozanolixizumab in the Treatment of Generalized Myasthenia Gravis.

Advances in therapy·2026

Related Experiment Video

Updated: May 5, 2026

Mimicking the Function of Signaling Proteins: Toward Artificial Signal Transduction Therapy
12:24

Mimicking the Function of Signaling Proteins: Toward Artificial Signal Transduction Therapy

Published on: September 29, 2016

6.4K

A users' guide to understanding therapeutic substitutions.

Edward J Mills1, David Gardner2, Kristian Thorlund3

  • 1Faculty of Health Sciences, University of Ottawa, 43 Templeton Street, Ottawa, Canada K1N6X1; Centre for Clinical Epidemiology and Evaluation (C2E2), University of British Columbia, 828 West 10th Ave, Research Pavilion, Vancouver, Canada, V5Z 1M9.

Journal of Clinical Epidemiology
|December 3, 2013
PubMed
Summary

Making therapeutic substitutions requires careful consideration of drug similarities. This article guides decision-makers on evaluating biological mechanisms, evidence validity, and safety profiles to ensure comparable risk-benefit assessments for substituted medications.

Keywords:
Class effectsEvidence-based medicineGeneric substitutionsNetwork meta-analysisStatinsTherapeutic substitutions

More Related Videos

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

3.4K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

10.9K

Related Experiment Videos

Last Updated: May 5, 2026

Mimicking the Function of Signaling Proteins: Toward Artificial Signal Transduction Therapy
12:24

Mimicking the Function of Signaling Proteins: Toward Artificial Signal Transduction Therapy

Published on: September 29, 2016

6.4K
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

3.4K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

10.9K

Area of Science:

  • Pharmacology
  • Clinical Pharmacy
  • Health Policy

Background:

  • Therapeutic substitutions are frequently implemented across healthcare levels, including ministries of health, clinical practice, and pharmacy dispensing.
  • Limited guidance exists for healthcare professionals to assess the comparable risk-benefit profiles of different therapeutic agents.
  • Decision-makers face potential biases that complicate the differentiation between various therapeutic agents.

Purpose of the Study:

  • To provide guidance for evaluating therapeutic substitutions.
  • To address the complexities in differentiating therapeutic agents.
  • To use a problem-based format for analyzing substitution scenarios.

Main Methods:

  • The article employs a problem-based learning approach.
  • It examines biological mechanisms and dosages of therapeutic agents.
  • It assesses the validity of evidence supporting therapeutic substitutions.
  • It evaluates the safety and therapeutic effects of drugs.

Main Results:

  • Decision-makers must consider the similarity of biological mechanisms and doses across agents.
  • The validity of evidence must be comparable for all considered drugs.
  • Safety and therapeutic effects should be similar between the original drug and its potential substitute.

Conclusions:

  • Awareness of potential biases is crucial when differentiating therapeutic agents.
  • A systematic evaluation of biological, evidential, and clinical factors is necessary for informed therapeutic substitution decisions.
  • This approach ensures patient safety and maintains therapeutic efficacy.